8-K filing — Faeth Therapeutics, Inc. (SNSE)
Filed: 2026-06-18 AccNo: 0001193125-26-276093 Size: 142 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Sensei Biotherapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $55 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Reiterates Buy on Sensei Biotherapeutics, Maintains $55 Price Target
Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12
8-K filing — Sensei Biotherapeutics, Inc. (SNSE)
Filed: 2026-06-15 AccNo: 0001193125-26-270330 Size: 240 KB Item 1.02: Termination of a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits